Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

CA Cancer Journal for Clinicians

Volumn 62, Issue 6, 2012, Pages 394-399

  Maluccio, Mary ^a   Covey, Anne ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

decision making patient preferences; liver neoplasms

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; GADOXETIC ACID; IODINATED POPPYSEED OIL; SORAFENIB; YTTRIUM 90;

ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; BLAND PARTICLE EMBOLIZATION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTRAST ENHANCEMENT; CRYOABLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG ELUTING STENT; ECHOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LASER THERMOTHERAPY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MICROWAVE THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; REVIEW; STANDARDIZATION; STEREOTACTIC BODY RADIATION THERAPY; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ABLATION TECHNIQUES; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIOSURGERY;

EID: 84869475394     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21161     Document Type: Review

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Simard EP, Ward EM, Siegel R, Jemal A,. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62: 118-128.
4. Okuda K,. Hepatocellular carcinoma. J Hepatol. 2000; 32 (suppl 1): 225-237.
5. Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort [published online ahead of print May 23, 2012]. Int J Cancer. doi: 10.1002/ijc.27645.
6. Bruix J, Sherman M,; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
7. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7: 350-391.
8. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48: 599-641.
9. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enchanced MR imaging. Radiology. 2011; 261: 834.
10. Kudo M,. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology. 2011; 81 (suppl 1): 73-85.
11. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28: 751-755.
12. Llovet JM, Bru C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
13. Kaseb AO, Hassan MM, Lin E, et al. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011; 117: 2478-2488.
14. Kaseb AO, Abbruzzese JL, Vauthey JN, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IFG-1 into CLIP score. Oncology. 2011; 80: 373-381.
15. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
16. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002; 8: 765-774.
17. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007; 246: 502-509; discussion 509-511.
18. Hanje AJ, Yao FY,. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant. 2008; 13: 234-240.
19. Salhab M, Canelo R,. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011; 7: 463-475.
20. Gluer AM, Cocco N, Laurence JM,. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012; 14: 285-290.
21. Takuma Y, Nouso K,. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 2010; 16: 1436-1441.
22. Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008; 19: 862-869.
23. Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT,. Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol. 2010; 21: 522-526.
24. Llovet JM, Real MI, Montana X, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739.
25. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224: 47-54.
26. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D,. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006; 17 (2 Pt 1): 217-223.
27. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009; 115: 616-623.
28. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56: 1330-1335.
29. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140: 497-507.e2.
30. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010; 138: 52-64.
31. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55: 1309-1316.
32. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12: 218-225.
33. Lo SS, Dawson LA, Kim EY, et al. Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med. 2010; 9: 404-410.
34. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81: e447-e453.
35. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012; 118: 3191-3198.
36. Yan K, Chen MH, Yang W, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol. 2008; 67: 336-347.
37. Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005; 16: 955-961.
38. Lencioni R, Cioni D, Della Pina C, Crocetti L,. Hepatocellular carcinoma: new options for image-guided ablation. J Hepatobiliary Pancreat Sci. 2010; 17: 399-403.
39. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569-577; quiz 578.
40. Kuang M, Xie XY, Huang C, et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011; 15: 2165-2171.
41. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 4293-4300.
42. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
43. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
44. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF,. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3960-3967.
45. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47: 2117-2127.